Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 15/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992614 | 1.00 | ALOX5 (0.44) | ALOX5MEN1KMT2ACISD1L3MBTL1 | |
| SCHEMBL2996287 | 0.87 | ALOX5 (0.40) | ALOX5MEN1KMT2ACISD1ALDH1A1 | |
| SCHEMBL2996292 | 0.87 | ALOX5 (0.40) | ALOX5MEN1KMT2ACISD1ALDH1A1 | |
| SCHEMBL2995795 | 0.87 | DYRK3 (0.39) | ALOX5MEN1KMT2ACISD1DYRK3 | |
| SCHEMBL2995792 | 0.87 | DYRK3 (0.39) | ALOX5MEN1KMT2ACISD1DYRK3 | |
| SCHEMBL2998823 | 0.87 | MEN1 (0.41) | ALOX5MEN1KMT2ACISD1L3MBTL1 | |
| SCHEMBL2998818 | 0.87 | MEN1 (0.41) | ALOX5MEN1KMT2ACISD1L3MBTL1 | |
| SCHEMBL4586253 | 0.87 | MEN1 (0.41) | ALOX5MEN1KMT2ACISD1L3MBTL1 | |
| SCHEMBL2993909 | 0.86 | CISD1 (0.39) | ALOX5MEN1KMT2ACISD1DYRK3 | |
| SCHEMBL2993913 | 0.86 | CISD1 (0.39) | ALOX5MEN1KMT2ACISD1DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| EP-2164494-A1 | METHODS OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150837-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | ALOX5 4155/4885MEN1 3889/4885KMT2A 3294/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | ALOX5 2869/4885MEN1 37/4885KMT2A 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.